Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Subject aged between 18 and 75 years.
Subject has histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.
Subject has at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
Subject has an ECOG score of 0-1 and is expected to survive more than 3 months;
Subjects have a good level of organ function.

Subject suitable for potentially curative surgery.
The subject confirmed by tissue or cytology as other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, etc.
The subject has previously received gemcitabine and nab-paclitaxel combination therapy within 6 months of progression or intolerance.

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer